Deep Bio

Deep Bio develops AI software, primarily its DeepDx® suite, to assist medical professionals in cancer pathology diagnostics. The platform analyzes whole-slide images of tissue specimens to detect cancer, score its severity (e.g., Gleason scores for prostate cancer), and quantify specific biomarkers. By integrating state-of-the-art deep learning technology, Deep Bio aims to improve the accuracy, consistency, and reproducibility of diagnoses, addressing challenges like pathologist shortages and diagnostic variability. The DeepDx® solutions are designed for various cancer types, including prostate and breast cancer, and provide metrics that are difficult to measure manually. This allows clinicians to optimize treatment decisions and enhance patient care. The company also offers DeepCDx™, an AI-enabled drug discovery solution to guide biopharmaceutical companies in developing new drugs by leveraging data and AI for diagnostic solutions.